Browse Drug Recalls
1,733 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,733 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,733 FDA drug recalls in 2015.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Apr 13, 2015 | EPINEPHrine HCl 4 mg added to 250 mL 0.9% Sodium Chloride Injection USP (16 m... | Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, ... | Class I | Pharmedium Services, LLC |
| Apr 13, 2015 | EPINEPHrine HCl 16 mg added to 250 mL 0.9% Sodium Chloride Injection USP (64 ... | Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, ... | Class I | Pharmedium Services, LLC |
| Apr 13, 2015 | oxyTOCIN 15 Units added to 250 mL 5% Dextrose Injection USP, packaged in 250 ... | Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, ... | Class I | Pharmedium Services, LLC |
| Apr 13, 2015 | EPINEPHrine HCl 1 mg added to 250 mL 0.9% Sodium Chloride Injection USP (4 mc... | Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, ... | Class I | Pharmedium Services, LLC |
| Apr 13, 2015 | Fluoxetine Capsules USP, 10 mg, in 100-count bottles, Rx only, Manufactured b... | Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity ... | Class II | Teva Pharmaceuticals USA |
| Apr 13, 2015 | HEPARIN Sodium Injection USP 25,000 USP Units added to 250 mL 5% Dextrose Inj... | Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, ... | Class I | Pharmedium Services, LLC |
| Apr 13, 2015 | Ketorolac Tromethamine Inj. USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose via... | Crystallization | Class II | Hospira Inc. |
| Apr 13, 2015 | Ketorolac Tromethamine Inj. USP, 60 mg (30 mg/mL), 2 mL Fill, Single-dose via... | Crystallization | Class II | Hospira Inc. |
| Apr 12, 2015 | Testosterone Cypionate 200 mg/mL in Sesame oil, 10 mL amber glass vial, Rx On... | Incorrect Product Formulation: Vials labeled as Testosterone Cypionate 200 mg/mL in Sesame Oil ar... | Class I | Stroheckers Inc Pharmacy |
| Apr 10, 2015 | ImproVue Ophthalmic Lubricant Drops (1.7% Hypromellose), 1 Single Use Syringe... | Failed pH specification | Class III | Oasis Medical, Inc. |
| Apr 10, 2015 | MONISTAT 1 SIMPLE CURE (Miconazole Nitrate Vaginal Insert) 1200 mg ovule, 1-D... | Marketed without an approved NDA/ANDA: The distributed units of Monistat 1 Simple Cure include on... | Class III | Medtech Products, Inc. |
| Apr 7, 2015 | Olanzapine, Orally Disintegrating Tablets, 20 mg, 30-count bottle, Rx only, M... | Subpotent drug | Class III | Apotex Inc. |
| Apr 7, 2015 | Olanzapine, Orally Disintegrating Tablets, 10 mg, a) 30-count bottle (NDC 605... | Subpotent drug | Class III | Apotex Inc. |
| Apr 7, 2015 | 0.9% Sodium Chloride Injection, USP, 100 mL ADD-Vantage Unit, Rx only, Manufa... | Lack of Sterility Assurance: The product has the potential to leak at the administrative port. | Class II | Hospira Inc. |
| Apr 7, 2015 | Hydroxyzine Hydrochloride, oral solution, 10 mg per 5 mL, 16 fl oz (473 ml) b... | Failed Impurities/Degradation Specifications | Class II | Akorn, Inc. |
| Apr 7, 2015 | Olanzapine, Orally Disintegrating Tablets, 5 mg, a) 30-count bottle (NDC 6050... | Subpotent drug | Class III | Apotex Inc. |
| Apr 7, 2015 | Hydroxyzine Hydrochloride, oral solution, 10 mg per 5 mL, 16 fl oz (473 ml) b... | Failed Impurities/Degradation Specifications | Class II | Akorn, Inc. |
| Apr 2, 2015 | Acarbose Tablets 50 mg a)10 x 10 Unit Dose Tablets per Blister Pack, b)100 co... | Subpotent Drug: The firm received an out of specification result for Assay (potency was below spe... | Class II | Boehringer Ingelheim Roxane Inc |
| Mar 31, 2015 | C-Topical 4% CII (cocaine hydrochloride), topical solution, 4 ml bottle, (NDC... | Labeling: Label mix-up; bottles were incorrectly labeled as 10 mL instead of correctly labeled as... | Class II | Cody Laboratories, Inc. |
| Mar 26, 2015 | Fexofenadine Hydrochloride Tablets, USP 60 mg, Allergy, Non-Drowsy, Antihista... | Failed Impurities/Degradation Specifications: the manufacturer, recalled product due to slightly ... | Class III | Mylan Institutional, Inc. (d.b.a. UDL Laborator... |
| Mar 26, 2015 | Cartia XT (diltiazem HCl extended-release capsules, USP), Once-A-Day Dosage, ... | Presence of Foreign Substance; fine residue or dust identified as aluminum may be on exterior of ... | Class III | Actavis Laboratories, FL, Inc. |
| Mar 25, 2015 | PROMETHAZINE VC WITH CODEINE SYRUP, EACH 5 ml contains: Codeine Phosphate 10... | Failed Impurities/Degradation Specifications: A stability lot was out of specification for a know... | Class III | Qualitest Pharmaceuticals |
| Mar 25, 2015 | GLIPIZIDE and METFORMIN HYDROCHLORIDE Tablets, USP, 2.5 mg/500 mg, 100 ct Bot... | Failed Impurities/Degradation Specifications: Out of specification for unknown impurity. | Class II | Heritage Pharmaceuticals, Inc. |
| Mar 24, 2015 | Rose Bengal GloStrips (rose bengal) Ophthalmic Strips USP, 1.3 mg per strip, ... | Failed Content Uniformity Specifications: The product may not meet finished product release speci... | Class III | Nomax Inc |
| Mar 24, 2015 | 0.9% Sodium Chloride Injection, USP, in 250mL VIAFLEX Plastic bags, Manufactu... | Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) | Class I | Baxter Healthcare Corp. |
| Mar 24, 2015 | Fluorescein Sodium Ophthalmic Strips USP, 0.6 mg per strip, labeled as 1) Flu... | Failed Content Uniformity Specifications: The product may not meet finished product release speci... | Class III | Nomax Inc |
| Mar 24, 2015 | 5% Dextrose Injection, USP, 250mL VIAFLEX Plastic bags, Manufactured by Baxte... | Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) | Class I | Baxter Healthcare Corp. |
| Mar 24, 2015 | Fluorescein Sodium Ophthalmic Strips USP, 1.0 mg per strip, labeled as 1) FUL... | Failed Content Uniformity Specifications: The product may not meet finished product release speci... | Class III | Nomax Inc |
| Mar 24, 2015 | Lactated Ringers Injection, USP, 250mL VIAFELX Plastic bags, Manufactured by ... | Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) | Class I | Baxter Healthcare Corp. |
| Mar 24, 2015 | 10% Dextrose Injection, USP, 250mL VIAFLEX Plastic bags, Manufactured by Bax... | Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) | Class I | Baxter Healthcare Corp. |
| Mar 23, 2015 | Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use... | Presence of Particulate Matter | Class I | Mylan Institutional LLC |
| Mar 23, 2015 | 0.9% Sodium Chloride Injection, USP, 50 mL, VIAFLEX Plastic Container Multi P... | Lack of Assurance of Sterility; increased complaints received for leaks | Class II | Baxter Healthcare Corp |
| Mar 23, 2015 | Gemcitabine for Injection, USP, 200 mg*/vial, Lyophilized powder in a Single-... | Presence of Particulate Matter | Class I | Mylan Institutional LLC |
| Mar 23, 2015 | Gemcitabine for Injection, USP, 1 g*/vial, Lyophilized powder in a Single-Use... | Presence of Particulate Matter | Class I | Mylan Institutional LLC |
| Mar 23, 2015 | Clinimix E 5/20 sulfite-free (5% amino-acid with electrolytes in 20% dextrose... | Lack of Assurance of Sterility; increased complaints received for leaks | Class II | Baxter Healthcare Corp |
| Mar 18, 2015 | CARBOplatin Injection 450 mg/45 mL (10 mg/mL), 45 mL packaged in a 100 mL Mul... | Presence of Particulate Matter | Class I | Mylan Institutional LLC |
| Mar 18, 2015 | 5% Dextrose Injection, USP, 1000mL in VIAFLEX Plastic Container, Rx only, Man... | Lack of Assurance of Sterility. Complaints were receive of missing closures and/or leaks which ma... | Class II | Baxter Healthcare Corp. |
| Mar 18, 2015 | Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, pac... | Presence of Particulate Matter | Class I | Mylan Institutional LLC |
| Mar 18, 2015 | 0.9% Sodium Chloride Injection, USP, 500 mL in VIAFLEX Plastic Container, Rx ... | Lack of Assurance of Sterility. Complaints were receive of missing closures and/or leaks which ma... | Class II | Baxter Healthcare Corp. |
| Mar 17, 2015 | Papaverine/phentolamine/prostaglandin 16/0.5/0.005 mg/mL Injection, Fallon We... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | Hydroxocobalamin 1) 1000mcg/mL, 2) 5mg/0.5mL, 3) 5000mcg/0.2mL injection, Fal... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | Prostaglandin Rx, dispensed in 5 ml vials: 1) 10 mcg/mL Injection, 2) 22.5 mc... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | Methylcobalamin/B-Complex Rx 2.5/103 mg/mL Injection, Fallon Wellness Pharmac... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | Methylcobolamin 1) 6500 mcg/0.26mL, 2) 1000 mcg/0.08mL, 3) 5000mcg/mL, 4) 300... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | Papaverine/phentolamine/prostaglandin 30/1/0.02 mg/mL Injection, Fallon Welln... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION, USP 800 mg/ 160 mg per 5mL... | Failed Dissolution Specifications: Out of specification for dissolution of sulfamethoxazole. | Class II | Akorn, Inc. |
| Mar 17, 2015 | Papaverine/phentolamine/prostaglandin 30/1/0.01mg/mL Injection, Fallon Wellne... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | Papaverine/phentolamine/prostaglandin 30/1/0.025 mg/mL Injection, Fallon Well... | Lack of assurance of sterility | Class II | Fallon Wellness Pharmacy, L.L.C. |
| Mar 17, 2015 | SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION, USP,200 mg/ 40 mg per 5mL,... | Failed Dissolution Specifications: Out of specification for dissolution of sulfamethoxazole. | Class II | Akorn, Inc. |
| Mar 17, 2015 | SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION, USP,200 mg/ 40 mg per 5mL,... | Failed Dissolution Specifications: Out of specification for dissolution of sulfamethoxazole. | Class II | Akorn, Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.